Where would I Invest $10,000 in ASX 200 Shares in February?

If the goal is to invest $10,000 in any 3 ASX 200 stocks in February, I would pick these three diversified companies which stand out due to strong momentum, solid fundamentals and clear growth catalysts.

Deep Yellow Limited (ASX: DYL)

Deep Yellow Limited (ASX: DYL) surged 7.14% by the afternoon trade on Tuesday as it regained momentum from the brief pullback last week and now has a market capitalisation of $2.49 billion.

The company reported solid quarterly progress at its flagship Tumas Project in Namibia where detailed engineering is now over 60% complete, bulk earthworks have reached 24% and a power supply agreement has been executed which keeps the project on track for a final investment decision.

The balance sheet remains a key strength with cash of $187.1 million at 31 December 2025 which provides funding flexibility as development advances across the Tumas, Mulga Rock and Alligator River projects.

The stock has doubled over the past 12 months and a major milestone during the December 2025 quarter was the completion of an Independent Technical Expert report at Tumas which identified no material flaws.

The company benefits from strong AI power demand tailwind and with multiple advanced assets in tier one jurisdictions and a clear path to production, the company is well-positioned to create substantial shareholder value.

Zip Co Limited (ASX: ZIP)

Zip Co Limited (ASX: ZIP) surged 6.28% by afternoon trade on Tuesday and the company is now valued at a market capitalisation of $3.34 billion.

In its 1Q FY26 update released on 20 October 2025, Zip reported record cash EBITDA of $62.8 million, up 98.1% year-on-year, which was supported by operating leverage and tight cost control across ANZ and the US.

Total transaction volume increased 38.7% year-on-year to $3.9 billion while total income rose 32.8% to $321.5 million which reflects the expanding scale of the US business.

The US segment remained the main growth driver with TTV and revenue up 47.2% and 51.2% respectively in USD terms which was supported by customer growth of 12.2% and stable net bad debts of around 1.6% of TTV.

As part of its capital management framework, Zip has bought back 21.4 million shares for a total value of $58.4 million to date under its on-market share buy-back program of up to $100 million.

Management has upgraded its FY26 US TTV growth outlook to above 40% in USD terms which positions Zip for continued profitability as scale benefits, funding efficiency and customer engagement improve further.

Mesoblast Limited (ASX: MSB)

Mesoblast Limited (ASX: MSB) rose 5.49% by afternoon trade on Tuesday as investors reacted to stronger commercial momentum with the company now valued at a market capitalisation of $3.23 billion.

For the December 2025 quarter, Mesoblast reported net revenues of US$30 million from its flagship product Ryoncil, supported by a 60% quarter-on-quarter increase in gross sales to US$35 million.

Ryoncil has continued to see higher adoption after FDA approval for paediatric steroid refractory acute graft versus host disease, with early real-world data showing an 84% survival rate among the first 25 patients who completed the initial treatment cycle.

A major financial update during the quarter was the setup of a US$125 million non-dilutive credit facility at a fixed interest rate of 8% which lowered the company’s cost of capital and extended its funding runway.

Mesoblast ended December with US$130 million in cash and on the development side, the company is preparing to begin a pivotal trial to extend Ryoncil into adult patients which is a market that is estimated to be around three times larger than the paediatric indication. 

(Source: Company Reports)